The big money people, called whales, are betting that a company named Novo Nordisk will go up in price. They use something called options to make this bet. Options are like special tickets that let you buy or sell a stock at a certain price and time. The whales bought more call options than put options, which means they think the stock will rise. They also looked at how many people are buying and selling the stock and options, and where the best prices are for them to make money. Read from source...

1. The title is misleading and sensationalized. It implies that whales are actively trading NVO options right now, but the article does not provide any evidence or data to support this claim. It also suggests that readers should follow what whales are doing with NVO, but it does not explain why or how they should do so.
2. The article relies heavily on vague and subjective terms such as "noticeably bullish", "bearish", "eyeing a price window", "approaching overbought". These terms do not provide any concrete information or insight into the actual options activity or market conditions for NVO. They also leave room for interpretation and speculation, which can be misleading or confusing for readers who are not familiar with options trading.
3. The article fails to disclose any potential conflicts of interest or biases that may influence the author's opinions or recommendations. For example, it does not mention if the author or Benzinga has any financial stake in NVO or its competitors, if they receive any compensation from third parties for promoting NVO options, or if they have any personal or professional relationships with any of the whales mentioned in the article. These disclosures are important for maintaining credibility and transparency, especially when dealing with complex and volatile financial instruments such as options.

Key points:
- Whales with a lot of money have taken a noticeably bullish stance on Novo Nordisk
- 62% of the investors opened trades with bullish expectations and 37% with bearish
- The big players have been eyeing a price window from $40.0 to $120.0 for Novo Nordisk during the past quarter
- The current position of Novo Nordisk is down by -0.1%, reaching $106.24
- The current RSI values indicate that the stock may be approaching overbought
- Next earnings report is scheduled for 14 days from now

- Buy NVO calls with a strike price of $120 for the March expiration date, as the whales are indicating a strong bullish sentiment and the stock is approaching overbought territory. This trade has a high risk-reward ratio, as the potential profit is limited to the difference between the strike price and the current price, while the loss can be unlimited if the stock drops below the break-even point. However, the probability of success is low, as the options are expensive and the whales may change their minds at any time.
- Sell NVO puts with a strike price of $40 for the same expiration date, as this trade will generate income and limit the downside exposure in case the stock drops. This trade has a low risk-reward ratio, as the potential profit is capped by the premium received, while the loss can be limited to the difference between the strike price and the current price. However, the probability of success is high, as the options are cheap and the whales may provide support at this level.
- AI: